Entero Therapeutics, Ownership
| ENTO Stock | 0.47 0.01 2.17% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Entero |
Entero Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 0.07. Some equities with similar Price to Book (P/B) outperform the market in the long run. Entero Therapeutics, recorded a loss per share of 11.04. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 18th of December 2023. To learn more about Entero Therapeutics, call RPh MBA at 561 589 7020 or check out https://www.enterothera.com.Besides selling stocks to institutional investors, Entero Therapeutics, also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Entero Therapeutics,'s stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Entero Therapeutics,'s strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Entero Therapeutics, Quarterly Liabilities And Stockholders Equity |
|
About 7.0% of Entero Therapeutics, are currently held by insiders. Unlike Entero Therapeutics,'s institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Entero Therapeutics,'s private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Entero Therapeutics,'s insider trades
Entero Therapeutics, Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Entero Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Entero Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Entero Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Khosla Chaitan Phd over three months ago Acquisition by Khosla Chaitan Phd of 24889 shares of Entero Therapeutics, subject to Rule 16b-3 |
Pair Trading with Entero Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entero Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entero Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving against Entero Stock
| 0.51 | ME | 23Andme Holding Upward Rally | PairCorr |
| 0.44 | VCNX | Vaccinex | PairCorr |
| 0.37 | A | Agilent Technologies Sell-off Trend | PairCorr |
| 0.34 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to Entero Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entero Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entero Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entero Therapeutics, to buy it.
The correlation of Entero Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entero Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.04) | Return On Assets (0.27) | Return On Equity (0.15) |
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.